drugset / Trial / NCT00745420

Summary

Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause organ damage, stroke, and intense pain episodes. A blood stem cell transplant is a treatment option for someone with a severe form of the disease. Prior to undergoing a transplant, people typically receive a conditioning regimen of high doses of chemotherapy and other medications to prepare the body to accept the transplant. A conditioning regimen that uses lower doses of chemotherapy and medications may be safer for transplant recipients. This study will evaluate the safety and effectiveness of blood stem cell transplants, using bone marrow from unrelated donors, in children with severe SCD who receive a reduced intensity conditioning regimen prior to the transplant.

Timeline

Start
2008-08
Primary completion
2015-07
Completion
2016-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Alemtuzumab Monoclonal antibody 10 mg Intravenous
Background Alemtuzumab Monoclonal antibody 15 mg Intravenous
Background Alemtuzumab Monoclonal antibody 20 mg Intravenous
Background Cyclosporine Peptide
Background Fludarabine Small molecule 30 mg/m2 Intravenous
Background Melphalan Small molecule 140 mg/m2 Intravenous
Background Methotrexate Small molecule 7.5 mg/m2
Background Methylprednisolone Other / unclassified
Background Prednisone Other / unclassified
Background Tacrolimus Small molecule

Indications